Abstract
Inhibitors of HIV-1 protease are designed to, generally, act specifically on this enzyme class, characterized by its high affinity and high complementarity to the catalytic site of the protein, intrinsically competing with the natural substrates. The goal of antiretroviral therapy is therefore to slow the progression of immunodeficiency and restore, as much as possible, immunity, increasi…